Inotiv, Inc.
NOTVQ Healthcare Diagnostics & Research
Inotiv, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $513.0 million, up 4.54% from fiscal 2024. In the quarter to March 2026, revenue fell 5.37%, EPS fell 113.6%, free cash flow grew 82.7% and total debt rose 5.98%, each against the same quarter a year earlier.
Follow NOTVQ
Inotiv, Inc. (NOTVQ) EV/Sales
As of 27 July 2026, Inotiv, Inc. (NOTVQ) trades at a EV/Sales of 1.6×. Over the past ten years it has ranged from 0.4× (January 2017) to 10.0× (September 2021); the current reading is higher than 80% of that period. That is below the Diagnostics & Research industry median of 5.5× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.6× | 88.76% |
| FY2024 | 0.8× | 15.89% |
| FY2023 | 0.7× | (46.24%) |
| FY2022 | 1.4× | (69.09%) |
| FY2021 | 4.4× | 241.49% |
| FY2020 | 1.3× | 5.54% |
| FY2019 | 1.2× | 38.22% |
| FY2018 | 0.9× | 15.84% |
| FY2017 | 0.8× | 10.20% |
| FY2016 | 0.7× | (11.88%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 1.6× | 1.23% |
| Dec 2025 | 1.6× | (1.68%) |
| Sep 2025 | 1.6× | 78.52% |
| Jun 2025 | 0.9× | (5.45%) |
| 41 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DMTKQ DermTech, Inc. compare | −2.5× |
| ISPC iSpecimen Inc. compare | −1.1× |
| BIAF bioAffinity Technologies, Inc. compare | −0.1× |
| XWEL XWELL, Inc. compare | 0.0× |
| AWHL Aspira Women's Health Inc. compare | 1.4× |
| NOTVQ Inotiv, Inc. | 1.6× |
| PRPH ProPhase Labs, Inc. compare | 1.8× |
| NDRA ENDRA Life Sciences Inc. compare | 2.2× |
| TTOO T2 Biosystems, Inc. compare | 6.3× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)